Back to search

Article

Clinical performance evaluation of a highly sensitive Safe-SeqS plasma circulating-tumor DNA assay for the detection of RAS and BRAF V600E mutations in metastatic colorectal cancer

2026-06-16

Abstract excerpt

<title>Abstract</title> <p> Background We developed a circulating tumor DNA (ctDNA) assay for detecting <italic>RAS</italic> and <italic>BRAF</italic> V600E mutations using next-generation sequencing-based Safe-Sequencing System (Safe-SeqS) technology and evaluated its clinical performance. Methods Patients with metastatic colorectal cancer were enrolled. Concordance of <italic>RAS</italic> mutational st...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
81743259-5cc4-59b4-9067-92b341861861
DOI
10.21203/rs.3.rs-9883234/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical performance evaluation of a highly sensitive Safe-SeqS plasma circulating-tumor DNA assay for the detection of RAS and BRAF V600E mutations in metastatic colorectal cancerDOI 10.21203/rs.3.rs-9883234/v1
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.Semantic proximity
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.Semantic proximity
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal CancerSemantic proximity
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.Semantic proximity
Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancerSemantic proximity
BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC StudySemantic proximity
Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS MutationSemantic proximity
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.Semantic proximity
Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.Semantic proximity
Concordance of Acquired Mutations between Metastatic Lesions and Liquid Biopsy in Metastatic Colorectal Cancer Treated with Anti-EGFR TherapySemantic proximity
Select a neighboring publication to make it the new centre.